[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-563320-105":53,"doc-detail-563320-en":120},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":113,"head_meta":115,"extra_data":117,"updated_unix":119},105,"en","tirzepatide-mounjaro","Tirzepatide \"Mounjaro\"","","Medical overview of tirzepatide (Mounjaro) covering availability in Canada, regulatory status, and insurance coverage details, including discount and coupon access. Explains the dual GLP-1/GIP receptor mechanism and effects on glycemia, appetite, weight, and incretin response, with notes on use in type 2 diabetes and off-label type 1 diabetes. Summarizes common side effects, dosing escalation and maximum approved dose, pen formulation strengths, click-based dosing, and comparative potency versus Ozempic, plus cost and insurance-form identifier mentions.",{"@graph":63,"@context":112},[64,80,95],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":41,"@type":70,"position":76},"https://docshare.wps.com/template/letters/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/tirzepatide-mounjaro/563320/",4,{"url":78,"name":59,"@type":81,"author":82,"headline":59,"publisher":85,"fileFormat":88,"inLanguage":57,"description":61,"dateModified":89,"datePublished":89,"encodingFormat":88,"isAccessibleForFree":90,"interactionStatistic":91},"DigitalDocument",{"name":83,"@type":84},"Connor ","Person",{"url":68,"name":86,"@type":87},"DocShare","Organization","application/pdf","2026-10-12",true,{"@type":92,"interactionType":93,"userInteractionCount":4},"InteractionCounter",{"@type":94},"ViewAction",{"@type":96,"mainEntity":97},"FAQPage",[98,104,108],{"name":99,"@type":100,"acceptedAnswer":101},"What is tirzepatide (Mounjaro) and how does it work?","Question",{"text":102,"@type":103},"Tirzepatide is a “dual receptor agonist” that stimulates both the GLP-1 receptor and the GIP receptor. It reduces sugar and weight by suppressing appetite, delaying stomach emptying, and increasing insulin release via the incretin effect.","Answer",{"name":105,"@type":100,"acceptedAnswer":106},"What are the common side effects and who may have difficulty taking it?",{"text":107,"@type":103},"The only common side effects are nausea and vomiting. About 5% of individuals cannot take tirzepatide due to these side effects; many people experience mild initial side effects that settle over time.",{"name":109,"@type":100,"acceptedAnswer":110},"How is Mounjaro dosing administered with the pen, and how are doses adjusted?",{"text":111,"@type":103},"Mounjaro is given as a once-weekly subcutaneous injection with a starting dose of 2.5 mg weekly. The dose may be increased every 4 weeks by 2.5 mg, up to 15 mg weekly, and pen dosing uses “clicks” where a full discharge delivers the intended dose.","https://schema.org",{"og:url":78,"og:type":114,"og:title":59,"og:site_name":86,"og:description":61},"article",{"robots":116,"canonical":78},"index,follow",{"doc_id":118,"site_id":56},563320,1791828917,{"code":4,"msg":5,"data":121},{"doc_id":118,"user_id":122,"nickname":83,"user_avatar":123,"doc_module":9,"category_id":40,"category_name":41,"doc_title":59,"doc_description":61,"doc_content":124,"file_id":125,"file_url":126,"file_type":127,"file_size":128,"view_count":4,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":47,"language":129,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":130,"faqs":131,"seo_title":132,"seo_description":61,"update_tm":119,"read_time":73},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Dr. Tom Elliott MBBS, FRCPC Medical Director  \n400-210 W Broadway Vancouver, BC  \nV5Y 3W2 Canada  \nphone: fax:  \nemail:  \n604.683.3734  \n604.628.3821 [moa@bcdiabetes.ca](moa@bcdiabetes.ca)  \n2025-May-23  \nTirzepatide \"Mounjaro\"  \nTirzepatide (\"Mounjaro\") has been available in Canada since 2023-Nov. BC Pharmacare approval is still awaited. Tirzepatide is covered by 70% of third party insurers, a notable exception in British Columbia being [Pacific Blue Cross. Visit](Pacific Blue Cross. Visit mymounjaro.ca)[ ](Pacific Blue Cross. Visit mymounjaro.ca)[mymounjaro.ca](Pacific Blue Cross. Visit mymounjaro.ca), where by declaring you have diabetes, you can obtain a coupon for a 25-40% discount (see details below) on the regular retail price. Without registering [at](at mymounjaro.ca)[ ](at mymounjaro.ca)[mymounjaro.ca](at mymounjaro.ca), a single pen of Mounjaro will cost in excess of $800.  \nTirzepatide is a “dual receptor agonist” - it stimulates both the GLP-1 receptor (like semaglutide“Ozempic”) and unlike Ozempic it stimulates the GIP receptor as well. Tirzepatide powerfully reduces sugar and weight by suppressing appetite, by delaying stomach emptying (so people feel full longer) & by increasing the release of insulin from the body (the “incretin” effect) . As such tirzepatide has a major role in the treatment of overweight & obese individuals with Type 2 diabetes as well as obese non-diabetic individuals (Health Canada approval is awaited for simple obesity) .  \nTirzepatide is widely used “off-label” in long-standing Type 1 diabetes for both weight loss and reduction in insulin requirement (reductions of 50% are often observed) . Tirzepatide has been used experimentally in newly diagnosed Type 1 diabetes where it appears to have a role in preserving and increasing proliferation of beta cells, the cells that produce insulin. Click here for more on GLP-1s in T1D.  \nThe only common side-effect of tirzepatide is nausea & vomiting. Approximately 5% of individuals cannot take tirzepatide because of these side-effects. Many individuals have mild initial  \nside-effects which settle with time. Tirzepatide does not increase the risk of cancer. It may slightly increase the incidence of pancreatitis & gallstones.  \nTirzepatide is given by subcutaneous injection once weekly. The starting dose is 2.5 mg weekly. The dose may be increased every 4 weeks by 2.5 mg at a time. The highest approved dose is 15 mg weekly (though 30 mg weekly has been used experimentally) . To get to the sugar and/or weight loss target the dose may be increased monthly from 2.5 weekly to 5.0, 7.5, 10.0, 12.5 and finally to 15.0 mg weekly as necessary.  \nIn approved dosing, Mounjaro is more potent than Ozempic for both the lowering of weight and sugar. In the United States, Mounjaro (=Zepbound) is also approved for the treatment of sleep apnea. By extrapolation Mounjaro 2.5 mg weekly is roughly equivalent to Ozempic 1 mg weekly. For a head-to-head comparison see Frias et al 2021 NEJM: Figures 1 & 2 from the Frias paper for sugar/glycemia & weight loss respectively are shown as screenshots at the end of this article.  \nSince 2025-Jan-2 Mounjaro has been available in a pen in Canada. Pens come in 2.5, 5.0, 7.5, 10.0, 12.5 and 15.0 mg formulations: each pen contains 4 shots of that strength i.e. sufficient for 4 weeks. For more on Mounjaro pens see this  1 minute video. All pen formulations, 2.5, 5.0, 7.5, 10.0, 12.5 and 15.0 mg contain the same volume = 0.6 ml. A full discharge of each pen equals 60  \n“clicks” and delivers ¼ of this volume. Thus a full discharge of 60 clicks delivers the intended dose for each pen. Each pen holds 240 clicks.  \nBelow are DIN & UPC numbers required for completion of insurance forms.  \n[With](With mymounjaro.ca)[ ](With mymounjaro.ca)[mymounjaro.ca](With mymounjaro.ca) registration the 2.5 & 5 mg pens are discounted 25%, the 7.5 & 10 mg pens are discounted 35% & the 12.5 & 15 mg pens are discounted 40% . With those discounts applied, below","cbCaicbXBANZky7C","https://ap.wps.com/l/cbCaicbXBANZky7C","pdf",9526628,"English","# Overview\n## Availability and insurance coverage\n# Mechanism and clinical role\n## Type 2 diabetes and obesity\n## Off-label use in type 1 diabetes\n# Safety and side effects\n# Administration and dosing\n## Starting and escalation schedule\n## Pen formats and click calculations\n## Potency vs Ozempic\n# Pricing and practical notes\n## Wholesale vs retail costs\n## Discounted prices and off-label dosing notes","[{\"question\":\"What is tirzepatide (Mounjaro) and how does it work?\",\"answer\":\"Tirzepatide is a “dual receptor agonist” that stimulates both the GLP-1 receptor and the GIP receptor. It reduces sugar and weight by suppressing appetite, delaying stomach emptying, and increasing insulin release via the incretin effect.\"},{\"question\":\"What are the common side effects and who may have difficulty taking it?\",\"answer\":\"The only common side effects are nausea and vomiting. About 5% of individuals cannot take tirzepatide due to these side effects; many people experience mild initial side effects that settle over time.\"},{\"question\":\"How is Mounjaro dosing administered with the pen, and how are doses adjusted?\",\"answer\":\"Mounjaro is given as a once-weekly subcutaneous injection with a starting dose of 2.5 mg weekly. The dose may be increased every 4 weeks by 2.5 mg, up to 15 mg weekly, and pen dosing uses “clicks” where a full discharge delivers the intended dose.\"}]","Tirzepatide \"Mounjaro\" | PDF"]